Trials / Terminated
TerminatedNCT02423954
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Western Regional Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine Phase 2 dose of study drug
Detailed description
Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.
Conditions
- Advanced Cancer
- Pancreatic Cancer
- Renal Cell Cancer
- Non Small Cell Lung Cancer
- Colorectal Carcinoma
- Endometrial
- Uterine
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus | |
| DRUG | Irinotecan | |
| DRUG | Irinotecan + capecitabine | |
| DRUG | nivolumab |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2015-04-22
- Last updated
- 2018-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02423954. Inclusion in this directory is not an endorsement.